Hypera Pharma
Hypera Pharma, a leading player in the Brazilian pharmaceutical industry, is headquartered in São Paulo, Brazil. Founded in 2010, the company has rapidly established itself as a key provider of prescription and over-the-counter medications, focusing on therapeutic areas such as central nervous system disorders, dermatology, and consumer health. With a diverse portfolio of well-known brands, Hypera Pharma distinguishes itself through its commitment to innovation and quality, ensuring that its products meet the highest standards. The company has achieved significant market presence, becoming one of the largest pharmaceutical companies in Brazil, and has garnered recognition for its strategic acquisitions and robust growth trajectory. Hypera Pharma continues to enhance its position in the industry by prioritising research and development, aiming to improve health outcomes for patients across the region.
DitchCarbon Score
How does Hypera Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hypera Pharma's score of 36 is higher than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hypera Pharma's reported carbon emissions
Hypera Pharma, headquartered in Brazil, reported its carbon emissions data for the year 2021, with total emissions amounting to approximately 50,202,930 kg CO2e. This figure includes Scope 1 emissions of about 25,417,550 kg CO2e, Scope 2 emissions of around 8,665,850 kg CO2e, and Scope 3 emissions of approximately 16,119,530 kg CO2e. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and Scope 2 greenhouse gas emissions by 42% by the year 2030, using 2020 as the baseline year. This target has been validated through the Science Based Targets initiative (SBTi), ensuring alignment with the global goal of limiting temperature rise to 1.5°C. Additionally, Hypera Pharma is committed to measuring and reducing its Scope 3 emissions, which encompass indirect emissions from its value chain. Overall, Hypera Pharma's proactive approach to managing its carbon footprint reflects its dedication to sustainability and climate responsibility within the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|
| Scope 1 | 19,561,440 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 4,925,500 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 17,458,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hypera Pharma is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
